+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-small Cell Lung Cancer Therapeutics Market Research Report by Drug Class, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4968594
  • Report
  • June 2021
  • Region: Global
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Non-small Cell Lung Cancer Therapeutics Market Grew USD 20.82 Billion by 2026, at a CAGR of 7.57%

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Bristol Myers Squibb
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Orion Corporation
The Global Non-small Cell Lung Cancer Therapeutics Market size was estimated at USD 13.43 Billion in 2020 and expected to reach USD 14.40 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 7.57% from 2020 to 2026 to reach USD 20.82 Billion by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Non-small Cell Lung Cancer Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the Non-small Cell Lung Cancer Therapeutics Market was examined across Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites, Kinase Inhibitor, Microtubule Stabilizer, and PD-1/ PD-L1 Inhibitor.
  • Based on Geography, the Non-small Cell Lung Cancer Therapeutics Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Non-small Cell Lung Cancer Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Non-small Cell Lung Cancer Therapeutics Market, including Astellas Pharma Inc, AstraZeneca PLC, Bristol Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, Celgene Corporation, Eisai Co., Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Orion Corporation, Pfizer Inc, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Non-small Cell Lung Cancer Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Non-small Cell Lung Cancer Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Non-small Cell Lung Cancer Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Non-small Cell Lung Cancer Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Non-small Cell Lung Cancer Therapeutics Market?
6. What is the market share of the leading vendors in the Global Non-small Cell Lung Cancer Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Non-small Cell Lung Cancer Therapeutics Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Bristol Myers Squibb
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Orion Corporation
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Geography Outlook
3.5. Competitor Outlook

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of Non-small Cell Lung Cancer (NSCLC) across the globe due to increasing air pollution and smoking habits
5.1.1.2. Presence of a strong pipeline for NSCLC therapeutics
5.1.2. Restraints
5.1.2.1. High cost and lack of availability of the drug
5.1.3. Opportunities
5.1.3.1. Introduction of new targeted therapies and treatments
5.1.3.2. Adoption of advanced therapeutics in the developing countries
5.1.4. Challenges
5.1.4.1. Capital intensive treatment and procedures
5.2. Cumulative Impact of COVID-19
5.3. Porters Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry

6. Non-small Cell Lung Cancer Therapeutics Market, by Drug Class
6.1. Introduction
6.2. Angiogenesis Inhibitor
6.3. Epidermal Growth Factor Receptor Blocker
6.4. Folate Antimetabolites
6.5. Kinase Inhibitor
6.6. Microtubule Stabilizer
6.7. PD-1/ PD-L1 Inhibitor

7. Americas Non-small Cell Lung Cancer Therapeutics Market
7.1. Introduction
7.2. Argentina
7.3. Brazil
7.4. Canada
7.5. Mexico
7.6. United States
7.6.1. California
7.6.2. Florida
7.6.3. Illinois
7.6.4. New York
7.6.5. Ohio
7.6.6. Pennsylvania
7.6.7. Texas

8. Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market
8.1. Introduction
8.2. China
8.3. India
8.4. Indonesia
8.5. Japan
8.6. Malaysia
8.7. Philippines
8.8. South Korea
8.9. Thailand

9. Europe, Middle East & Africa Non-small Cell Lung Cancer Therapeutics Market
9.1. Introduction
9.2. France
9.3. Germany
9.4. Italy
9.5. Netherlands
9.6. Qatar
9.7. Russia
9.8. Saudi Arabia
9.9. South Africa
9.10. Spain
9.11. United Arab Emirates
9.12. United Kingdom

10. Competitive Landscape
10.1. FPNV Positioning Matrix
10.1.1. Quadrants
10.1.2. Business Strategy
10.1.3. Product Satisfaction
10.2. Market Ranking Analysis
10.3. Market Share Analysis
10.4. Competitive Scenario
10.4.1. Merger & Acquisition
10.4.2. Agreement, Collaboration, & Partnership
10.4.3. New Product Launch & Enhancement
10.4.4. Investment & Funding
10.4.5. Award, Recognition, & Expansion

11. Company Usability Profiles
11.1. Astellas Pharma Inc
11.2. AstraZeneca PLC
11.3. Bristol Myers Squibb
11.4. C.H. Boehringer Sohn AG & Ko. KG
11.5. Celgene Corporation
11.6. Eisai Co., Ltd
11.7. Eli Lilly and Company
11.8. F. Hoffmann-La Roche Ltd
11.9. GlaxoSmithKline PLC
11.10. Merck KGaA
11.11. Novartis International AG
11.12. Orion Corporation
11.13. Pfizer Inc
11.14. Sanofi S.A.
11.15. Takeda Pharmaceutical Company Limited

12. Appendix
12.1. Discussion Guide
12.2. License & Pricing
12.3. Contact Details

List of Tables
TABLE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 10. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 11. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 12. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 13. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 14. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 15. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 16. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 17. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 18. CALIFORNIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 19. FLORIDA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 20. ILLINOIS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 21. NEW YORK NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 22. OHIO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 23. PENNSYLVANIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 24. TEXAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 25. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 26. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 27. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 28. INDIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 29. INDONESIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 30. JAPAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 31. MALAYSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 32. PHILIPPINES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 33. SOUTH KOREA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 34. THAILAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 35. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 36. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 37. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 38. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 39. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 40. NETHERLANDS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 41. QATAR NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 42. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 43. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 44. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 45. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 46. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 47. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
TABLE 48. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: SCORES
TABLE 49. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 50. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 51. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: RANKING
TABLE 52. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 53. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 54. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 55. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 56. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 57. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: LICENSE & PRICING
TABLE 58. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: CONTACT DETAILS
Note: Product cover images may vary from those shown
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bristol Myers Squibb
  • C.H. Boehringer Sohn AG & Ko. KG
  • Celgene Corporation
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Merck KGaA
  • Novartis International AG
  • Orion Corporation
  • Pfizer Inc
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll